_LIMITED.webp)
Orphic Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 3.83 M
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 0.86%
- Profit Growth 103.21%
- Ebitda 451.04%
- Net Worth 15.03%
- Total Assets 5.03%
About Orphic Pharma (India)
Orphic Pharma (India) Limited (OPIL) is a Public Limited Indian Non-Government Company incorporated in India on 27 May 2003 and has a history of 21 years and eight months. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.83 M, as per Ministry of Corporate Affairs (MCA) records.
Mansukhlal Govani, Girish Agrawal, Arpit Agrawal, and Five other members serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239GJ2003PLC042431
-
Company No.
042431
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
27 May 2003
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Orphic Pharma (India) Limited offer?
Orphic Pharma (India) Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Mineral Supplement, Anti Infective Drugs & Medicines, Antibacterial Drugs, Anti Infective Agent, Digestive System Drugs & Medicines, Gastrointestinal Drugs, Pharmaceutical Medicine.
Who are the key members and board of directors at Orphic Pharma (India)?
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mansukhlal Govani
|
Director | 27-May-2003 | Current |
|
Girish Agrawal
|
Director | 27-May-2003 | Current |
|
Arpit Agrawal
|
Director | 21-Nov-2005 | Current |
|
Sunita Agrawal
|
Director | 27-May-2003 | Current |
|
Vinodbhai Govani
|
Director | 30-Aug-2010 | Current |
|
Kamal Batra
|
Director | 01-Oct-2022 | Current |
Financial Performance of Orphic Pharma (India).
Orphic Pharma (India) Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.86% increase. The company also saw a substantial improvement in profitability, with a 103.21% increase in profit. The company's net worth Soared by an impressive increase of 15.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orphic Pharma (India)?
In 2020, Orphic Pharma (India) had a promoter holding of 57.39% and a public holding of 42.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orphic Pharma (India)?
Unlock and access historical data on people associated with Orphic Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orphic Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orphic Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
